Study of E2511 for early Alzheimer's disease
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This study tests an experimental drug called E2511 in people with early Alzheimer's disease (mild cognitive impairment or mild dementia). The goal is to see if it is safe and how it affects the body, which may help slow down memory loss.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with mild cognitive impairment or mild Alzheimer's dementia.
- You are between 50 and 85 years old.
- You have evidence of amyloid buildup in the brain (from a blood test, spinal fluid test, or PET scan).
- You have a study partner who spends at least 8 hours a week with you and can attend visits.
- You are willing to have spinal taps (lumbar punctures) and MRI scans.
- You are not taking certain Alzheimer's medications (cholinesterase inhibitors) unless you can stop them for the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational injection for people in the early stages of Alzheimer's. It aims to see if the drug can safely slow down memory loss and brain changes.
This study tests an experimental drug called RO7568282 for people in the early stages of Alzheimer's disease. The goal is to see if it is safe and whether it can slow down memory loss and thinking problems.
This trial tests a new drug, NBI-1117567, for people with mild to moderate Alzheimer's disease who are already taking a standard Alzheimer's medication. The goal is to see if the new drug can help improve symptoms.
This trial tests a new medicine, VHB937, in people with early Alzheimer's (mild cognitive impairment or mild dementia). The goal is to see if it can slow down memory loss and thinking problems.
This early-stage trial tests whether ABBV-1758, a new drug given by injection, is safe and effective for people with Alzheimer's disease. The drug targets amyloid, a protein that builds up in the brains of people with Alzheimer's.
This trial tests an investigational drug called ALN-5288 for people with Alzheimer's disease. It aims to see if the drug is safe and how it affects the body.
Hear when a new Alzheimer’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.